Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05068674 · ClinicalTrials.gov registry record · Phase 1
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
A Phase 1 study of Chronic Ischemic Left Ventricular Dysfunction, sponsored by Joseph C. Wu.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05068674 is a Phase 1 study of Chronic Ischemic Left Ventricular Dysfunction that is actively recruiting participants, run by Joseph C. Wu. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05068674, a Phase 1 study of Chronic Ischemic Left Ventricular Dysfunction, is actively recruiting participants, sponsored by Joseph C. Wu.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
Conditions Studied
Interventions
- DRUG Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells
- DRUG Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells
- DRUG Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Study Locations (1)
California
- Stanford Hospital and Clinics - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05068674
The ClinicalTrials.gov registry entry for NCT05068674 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph C. Wu, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Ischemic Left Ventricular Dysfunction appearing as the primary indexed condition, and to 3 interventions - of which Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells is the first listed.
NCT05068674 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05068674 about?
NCT05068674 is a clinical study titled "Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction". This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
What is the current status of trial NCT05068674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-03-22. Estimated completion is 2028-10.
What conditions does trial NCT05068674 study?
This clinical trial studies the following conditions: Chronic Ischemic Left Ventricular Dysfunction.
What interventions are being tested in trial NCT05068674?
The interventions under investigation include: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells (DRUG), Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells (DRUG), Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells (DRUG).
Who is sponsoring clinical trial NCT05068674?
This trial is sponsored by Joseph C. Wu, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05068674 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.